DK2464370T3 - Modificerede vasoaktive intestinale peptider - Google Patents

Modificerede vasoaktive intestinale peptider Download PDF

Info

Publication number
DK2464370T3
DK2464370T3 DK10808864.2T DK10808864T DK2464370T3 DK 2464370 T3 DK2464370 T3 DK 2464370T3 DK 10808864 T DK10808864 T DK 10808864T DK 2464370 T3 DK2464370 T3 DK 2464370T3
Authority
DK
Denmark
Prior art keywords
gly val
vip
val pro
gly
pro gly
Prior art date
Application number
DK10808864.2T
Other languages
English (en)
Inventor
Homayoun Sadeghi
Andrew Turner
Suzanne Dagher
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2464370T3 publication Critical patent/DK2464370T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (10)

1. Farmaceutisk sammensætning, der omfatter et VIP-peptid, der omfatter (i) aminosyresekvensen ifølge SEQ ID NO: 13 med det N-terminale His ved position 2, og (ii) et N-terminalt methionin, der øger VIP-peptidets præference for VPAC2 versus VPAC1, og har et elastin-lignende peptid (ELP) ved C-terminus, der forlænger absorptionsfasen fra et injektionssted og forlænger kredsløbshalveringstiden, hvor ELP har fra 75 til 130 enheder af VPGXG (SEQ ID NO: 3), hvor sammensætningen af X er Val, Ala og Gly i et ratio på 5:2:3.
2. Farmaceutisk sammensætning ifølge krav 1, hvor VIP-peptidet har en relativ bindingspræference for VPAC2 frem for VPAC1 på mindst 2:1 eller mindst 50:1.
3. Farmaceutisk sammensætning ifølge krav 1 eller krav 2, hvor sammensætningen er formuleret til parenteral administration.
4. Sammensætning ifølge krav 3, hvor sammensætningen er formuleret til subkutan, intramuskulær eller intravenøs administration.
5. Sammensætning ifølge krav 3 eller krav 4 til anvendelse i en fremgangsmåde til behandling af hypertension, hjerteinsufficiens, myokardiefibrose eller reduktion af inflammatoriske reaktioner hos en person, hvilken fremgangsmåde omfatter administration til personen af en terapeutisk effektiv mængde af sammensætningen.
6. Sammensætning til anvendelse ved behandling af hypertension ifølge krav 5, hvor personen har hypertension udvalgt fra pulmonal hypertension, ukontrolleret essentiel hypertension og resistent hypertension.
7. Sammensætning til anvendelse ved behandling af inflammatoriske reaktioner ifølge krav 5, hvor personen har en inflammatorisk reaktion udvalgt fra hypersensitivitetsreaktioner af den forsinkede type, udvikling af autoreaktive T-ccllcr og en tilstand defineret ved inflammation af THI-typen og THI-autoimmunitet.
8. Sammensætning til anvendelse ifølge krav 7, hvor personen har en tilstand, der er defineret ved inflammation af THl-typen eller THI-autoimmunitet udvalgt fra arthritis, inflammatorisk tarmsygdom, Crohns sygdom, type 1-diabetes, multipel sklerose, transplantatafvisning, Sjøgrens syndrom, pancreatitis, uveoretinitis, keratitis og septisk shock.
9. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 5 til 8, hvor i fremgangsmåden sammensætningen indgives fra én til tre gange ugentligt, eller indgives dagligt.
10. Farmaceutisk sammensætning ifølge krav 3 eller krav 4 til anvendelse som et medikament.
DK10808864.2T 2009-08-14 2010-08-16 Modificerede vasoaktive intestinale peptider DK2464370T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23415109P 2009-08-14 2009-08-14
PCT/US2010/045605 WO2011020091A1 (en) 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides

Publications (1)

Publication Number Publication Date
DK2464370T3 true DK2464370T3 (da) 2017-05-15

Family

ID=43586545

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10808864.2T DK2464370T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive intestinale peptider
DK17163446.2T DK3311828T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive tarmpeptider

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17163446.2T DK3311828T3 (da) 2009-08-14 2010-08-16 Modificerede vasoaktive tarmpeptider

Country Status (19)

Country Link
US (5) US9029505B2 (da)
EP (2) EP2464370B1 (da)
JP (3) JP5801807B2 (da)
KR (2) KR101943420B1 (da)
CN (1) CN102596217B (da)
AU (3) AU2010282250B2 (da)
BR (1) BR112012003327A2 (da)
CA (1) CA2804755C (da)
DK (2) DK2464370T3 (da)
ES (2) ES2870914T3 (da)
HU (2) HUE054744T2 (da)
IL (1) IL218116A (da)
IN (1) IN2012DN02120A (da)
MX (2) MX339031B (da)
PL (2) PL2464370T3 (da)
PT (2) PT2464370T (da)
RU (1) RU2589255C2 (da)
SG (1) SG10201407329RA (da)
WO (1) WO2011020091A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
IN2012DN02120A (da) 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
US20130084277A1 (en) * 2011-08-24 2013-04-04 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
MX2014006391A (es) * 2011-11-28 2014-09-22 Phasebio Pharmaceuticals Inc Agentes terapéuticos que comprenden secuencias de aminoácidos de insulina.
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP3139949B1 (en) * 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
EP3220936A4 (en) 2014-11-21 2018-08-22 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
CN105753990B (zh) * 2014-12-19 2018-07-03 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
ES2822598T3 (es) * 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
WO2017152399A1 (zh) * 2016-03-09 2017-09-14 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
KR102646323B1 (ko) 2016-05-06 2024-03-13 이뮤노포지 주식회사 제어된 지속 방출을 위한 elp 융합 단백질
CN107056922A (zh) * 2016-12-24 2017-08-18 山东明鑫集团有限公司 一种具有降血糖作用的pacap多肽类似物的制备方法
US11786580B2 (en) * 2018-04-23 2023-10-17 Emory University VIP and VIP agonists, nanoparticles, and uses in inflammatory T-cell mediated disease
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR102719035B1 (ko) * 2020-04-20 2024-10-18 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
WO2021226244A1 (en) * 2020-05-05 2021-11-11 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
EP4326310A1 (en) 2021-04-20 2024-02-28 AdVita Lifescience AG Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome
DE102024001175A1 (de) 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.
CN119390812B (zh) * 2024-11-08 2025-07-29 三亚市私域大健康医院有限公司 一种治疗勃起功能障碍的干细胞外泌体组合物及其用途

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132746A (en) * 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4187852A (en) 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4500700A (en) 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4474851A (en) * 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4589882A (en) 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) * 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4605641A (en) 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4783523A (en) * 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US4870055A (en) * 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) * 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5830713A (en) * 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5514581A (en) * 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5641648A (en) * 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5496712A (en) * 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US6018030A (en) * 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5773249A (en) * 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US6184348B1 (en) * 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5770697A (en) * 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5234907A (en) * 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
ATE114458T1 (de) 1990-03-27 1994-12-15 Bioelastics Res Ltd Bioelastomeres arzneimittelabgabesystem.
DK0463450T3 (da) * 1990-06-26 1994-06-27 Sanwa Kagaku Kenkyusho Co Vasoaktive intestinale polypeptid-analoger og udnyttelsen heraf
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) * 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) * 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US5958881A (en) * 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) * 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) * 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) * 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
CA2187322A1 (en) * 1994-04-07 1995-10-19 Israel Rubinstein Vasoactive intestinal polypeptide
US5527610A (en) * 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5972406A (en) * 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US5624711A (en) * 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) * 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
WO1997009068A2 (en) 1995-09-01 1997-03-13 University Of Washington Interactive molecular conjugates
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
BR9707409A (pt) 1996-02-09 1999-04-13 Waleed Danho Sintese de análogo de vip
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) * 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043271A1 (en) 1998-02-27 1999-09-02 Bioelastics Research, Ltd. Injectable implants for tissue augmentation and restoration
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
ES2138561B1 (es) * 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US20020151458A1 (en) * 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
AU2249701A (en) * 1999-11-12 2001-06-06 David Bernstein Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6235264B1 (en) * 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) * 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE60033697D1 (de) 2000-02-18 2007-04-12 Dabur Res Foundation Sahibabad Radiomarkierte vip-analoge zur diagnose und therapie
AU2000265051A1 (en) 2000-02-18 2001-08-27 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6852834B2 (en) * 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
DE60137876D1 (de) * 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
AU2001273632A1 (en) 2000-06-23 2002-01-08 Drexel University Polymeric, fiber matrix delivery systems for bioactive compounds
WO2002043746A2 (en) * 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
SI1724284T1 (sl) * 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
AU2002322403A1 (en) * 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
KR20040065212A (ko) 2001-11-06 2004-07-21 센주 세이야꾸 가부시키가이샤 건조안 및 건조안과 연관된 질환의 치료제
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
JP2005535607A (ja) 2002-06-10 2005-11-24 モンドバイオテック・ラボラトリーズ・アンスタルト サルコイドーシスを治療するための血管作動性腸管ペプチドの生物活性をもつ化合物の使用
CN100381462C (zh) * 2002-11-27 2008-04-16 伊藤火腿株式会社 肽及含有所述肽的药物组合物
EP1633382A4 (en) * 2003-05-14 2009-08-05 Dow Corning REPEAT SEQUENCE PROTEIN-POLYMER-ACTIVE CONJUGATE, METHOD AND USES
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
WO2005004899A2 (de) 2003-07-14 2005-01-20 Mondobiotech Laboratories Anstalt Substanzen mit biologischer aktivität des vasoaktiven intestinalen peptids für die behandlung von interstitiellen lungenerkrankungen
WO2005014030A1 (en) * 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7776815B2 (en) * 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
EP1729790A4 (en) * 2004-03-29 2009-09-30 Robin Polt AMPHIPATHIC GLYCOPEPTIDES
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
EP1768689B1 (en) * 2004-06-11 2014-08-20 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
CA2575101A1 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
WO2006023367A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
KR20070067136A (ko) * 2004-10-08 2007-06-27 포베스 메디-테크 (리서치) 인코포레이티드 혈관작용성 장내 폴리펩티드 제약
US7723472B2 (en) * 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
EP3725299A1 (en) 2005-06-24 2020-10-21 Duke University A direct drug delivery system based on thermally responsive biopolymers
KR101057284B1 (ko) * 2005-10-26 2011-08-16 일라이 릴리 앤드 캄파니 선택적 ｖｐａｃ２ 수용체 펩티드 작동제
DE602006012358D1 (de) * 2005-11-18 2010-04-01 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
AU2006322656B2 (en) * 2005-12-09 2012-03-08 Vectus Biosystems Limited VIP fragments and methods of use
EP1971355B1 (en) * 2005-12-20 2020-03-11 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) * 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8367626B2 (en) * 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
CN101578373A (zh) 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
US8329640B2 (en) 2007-05-21 2012-12-11 Res International Sarl Peptides with improved properties having the biological activity of vasoactive intestinal peptide (VIP) and their use for the treatment of lung diseases
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
CN105727261A (zh) * 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
IN2012DN02120A (da) 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis

Also Published As

Publication number Publication date
IL218116A0 (en) 2012-04-30
EP2464370B1 (en) 2017-03-29
CA2804755A1 (en) 2011-02-17
KR20120062777A (ko) 2012-06-14
EP2464370A1 (en) 2012-06-20
EP2464370A4 (en) 2013-03-27
MX339031B (es) 2016-05-05
RU2012109553A (ru) 2013-09-20
PT3311828T (pt) 2021-05-05
EP3311828B1 (en) 2021-04-07
KR20170085611A (ko) 2017-07-24
BR112012003327A2 (pt) 2017-06-06
PL2464370T3 (pl) 2017-08-31
IL218116A (en) 2017-06-29
SG10201407329RA (en) 2015-01-29
IN2012DN02120A (da) 2015-08-21
JP2016000751A (ja) 2016-01-07
JP5801807B2 (ja) 2015-10-28
ES2870914T3 (es) 2021-10-28
AU2016200897B2 (en) 2017-10-12
EP3311828A1 (en) 2018-04-25
DK3311828T3 (da) 2021-06-28
RU2589255C2 (ru) 2016-07-10
AU2017279636B2 (en) 2019-09-12
US9029505B2 (en) 2015-05-12
AU2017279636A1 (en) 2018-01-18
KR101943420B1 (ko) 2019-04-17
CA2804755C (en) 2018-06-05
US20180008677A1 (en) 2018-01-11
US20160220642A1 (en) 2016-08-04
AU2010282250B2 (en) 2015-11-12
PL3311828T3 (pl) 2021-11-22
US9700598B2 (en) 2017-07-11
AU2016200897A1 (en) 2016-03-03
HUE032703T2 (en) 2017-10-30
US20250325635A1 (en) 2025-10-23
US20240091313A1 (en) 2024-03-21
JP2017066157A (ja) 2017-04-06
MX2012001979A (es) 2012-06-25
ES2624478T3 (es) 2017-07-14
AU2010282250A1 (en) 2012-04-05
PT2464370T (pt) 2017-05-17
MX366935B (es) 2019-07-31
WO2011020091A1 (en) 2011-02-17
CN102596217A (zh) 2012-07-18
JP2013501818A (ja) 2013-01-17
KR101887009B1 (ko) 2018-08-09
CN102596217B (zh) 2014-07-02
HUE054744T2 (hu) 2021-12-28
JP6229038B2 (ja) 2017-11-08
JP6069441B2 (ja) 2017-02-01
US20110178017A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
KR101943420B1 (ko) 변형된 혈관활성 장 펩티드
TWI784914B (zh) 包含長效胰島素類似物接合物及長效促胰島素肽接合物之治療糖尿病組成物
US10940182B2 (en) Use of modified vasoactive intestinal peptides in the treatment of hypertension
CN106715466A (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物
JP2013532970A (ja) 追加のジスルフィド結合を含有するヒトインスリン
JP5706331B2 (ja) 部位特異的にモノ抱合化されたインスリン分泌性のｇｌｐ−１ペプチド